FBFatma Bugdayci Basal

Fatma Bugdayci Basal

*This is an algorithmically generated author record based on publicly available information.

Fatma Bugdayci Basal has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quality of life and psychosocial challenges in metastatic breast cancer: the need for tailored interventions in Turkiye

    by Gul Basaran, Nuri Karadurmus, Fatma Bugdayci Basal, Violet Aroyo, Esra Savas, Ozge Fulya Ozturk Saglam, Pınar Gunay Aslan, Mahmut Gumus

    Metastatic breast cancer (MBC) patients face numerous psychosocial difficulties, including physical symptoms, psychological distress, and fears of mortality, which heavily impact their quality of life (QoL). This study addresses the need for culturally and regionally tailored psychosocial interventions by integrating insights from semi-structured interviews with selected stakeholders in Turkiye. Utilizing a qualitative research design, interviews were conducted with a patient association representative, psycho-oncologist, and oncologists with psychological expertise. These interviews, guided by literature-driven questions, lasted about three hours each and explored the challenges MBC patients face, the existing support structures, and the dynamics of patient-doctor interactions in Turkiye. Findings reveal that MBC patients experience significant psychological distress and QoL decline due to economic issues, fears of job loss, societal stigma, family dynamics, and limited psychological support. Effective doctor-patient communication, targeted psychological interventions, and comprehensive family support are essential. Experts advocate for a holistic, psycho-oncological approach, addressing both physical and psychological needs, with recommendations for multidisciplinary care, ongoing psychiatric support, and increased awareness. This study highlights the importance of tailored, patient-centered interventions to improve the QoL of MBC patients in Turkiye.


  • Open Access

    Immunogenicity and Safety of the Coronavac Vaccine in Patients with Cancer Receiving Active Systemic Therapy

    by Cengiz Karacin, Tulay Eren, Esra Zeynelgil, Goksen Inanc Imamoglu, Mustafa Altinbas, Ibrahim Karadag, Fatma Bugdayci Basal, Irem Bilgetekin, Osman Sutcuoglu, Ozan Yazici, et al.

    Aim: To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Methods: This multicenter, prospective, observational study was co... Tweetable abstract Immunogenicity developed with CoronaVac in 25 (59.5%) of 42 patients who received at least one cytotoxic drug and in all patients (n = 5) who received monoclonal antibody or immu...


  • The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC).

    by Irem Bilgetekin, Mehmet Dogan, Cengiz Karacin, Fatma Bugdayci Basal, Ece Esin, Gokhan Ucar, Ozlem Aydin Isak, Goksen Inanc Imamoglu, Gul Sema Yildiran Keskin, Ismail Erturk, et al.

    E15587 Background: Expanded RAS analysis is essential for the selection of biologic agents in mCRC. RAS mutations indicates anti-EGFR unresponsiveness. In this study, we aimed to investigate RAS and BRAF mutations by liquid biopsy at progression in patients with RAS mutant mCRC. Methods: Sixty patients with mCRC who harbored tissue RAS mutations were prospectively analyzed between July 2019 and April 2020. All the patients treated with chemotherapy plus bevacizumab combinations . The plasma samples of the patients were analyzed after progression of bevacizumab combinations. RAS mutation profile was evaluated in plasma using Idylla PCR-based molecular diagnostics method, which enables rapid detection of common mutations in RAS and BRAF genes in circulating tumor DNA (ctDNA). Kaplan-Meier method was used for survival analysis and log-rank test was performed for comparison of groups. Results: The median age of the patients was 60 years (IQR:35-83 years) and female was (n=23, 38.3%). Primary tumor was located in the left colon in 81.7% of all patients. There were 95.0% KRAS and 5% NRAS mutations in baseline tissue biopsy. As a result of liquid biopsy after progression, 55.0% of the patients had KRAS, 3.3% NRAS and 3.3% had BRAF mutations. The RAS mutation detected in 58.3% of the patients. While there was no significant difference in terms of clinicopathological features between wild type (RAS/BRAF) and mutant type (RAS/BRAF) determined by liquid biopsy, the overall survival (OS) of the wild type group was significantly longer than mutant group (43.8 vs. 20.4 months, p= 0.002). Conclusions: This study demonstrated that there may be changes in RAS/BRAF mutation from plasma analysis after progression in patients with mCRC. Since better survival in the patient group with wild type was detected compared to the RAS concordance group, the evaluation of RAS mutation status at the time of progression may be important in terms of disease prognosis and treatment options.

  • Worse patient–physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)

    by Ali Alkan, Arzu Yaşar, Zeynep Gülsüm Güç, Mustafa Gürbüz, Tuğba Başoğlu, Sema Sezgin Göksu, Fatma Buğdaycı Başal, Hacı Mehmet Türk, Özlem Özdemir, Havva Yeşil Çınkır, et al.

    Objective Fear of cancer recurrence (FCR) is an important psychological trauma associated with reduction in the quality of life, disruptions in the level of adjustment, emotional distress and anxiety. The purpose of the study was to evaluate the impact of patient–physician relationship on FCR. Methods The study was designed as a multicentre survey study. The cancer survivors, who were under remission, were evaluated with structured questionnaires. Patient–physician relationship (PPR) scale in which higher scores indicate better relationship and FCR inventory was used. Results Between January and April 2019, 1,580 patients were evaluated. The median age was 57.0 (19–88), and 66% were female. There was high level of FCR scores in 51% of participants. There was a negative correlation between PPR and FCR scores (r = −.134, p < .001). In multivariate analysis, young age, female gender, history of metastasectomy and worse PPR were associated with high levels of FCR. Conclusion It is the first data showing the adverse impact of worse PPR on FCR. The strategies to improve the PPR should be practised. In addition, the cancer survivors, who are under the risk of FCR, should be evaluated and managed.


  • Open Access

    Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel

    by Irem Bilgetekin, Fatma Bugdayci Basal, Havva Yesil Cinkir, Ece Esin, Berna Oksuzoglu, Umut Demirci

    Objective: To evaluate the efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) in docetaxel-naive and docetaxel-pretreated patients. Observational study. HSU Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey, from March 2017 to July 2019. A total of 67 patients with mCRPC were retrospectively evaluated. Castration-naive patients and non-metastatic patients were excluded from the study. Comorbid diseases, ECOG performance status, PSA response, and the radiological response of the patients were recorded. Kaplan-Meier method was used for survival analysis, and a Cox regression model was formed. The overall survival (OS) was significantly longer in patients with eastern cooperative oncology group performance status (ECOG PS) 0 (26.0 vs. 14.0 months, p=0.031), PSA response (26.0 vs. 7.0 months, p=0.002), radiological response (26.0 vs. 10.0 months, p=0.006) and duration of enzalutamide ≥9 months (26.0 vs. 7.0 months, p<0.001) compared to ECOG PS 1. According to Cox regression analysis, patients with PSA response had 0.35 fold (CI.95% 0.13-0.94) reduced the risk of death and 0.36-fold (CI.95%0.16-0.85) reduced the risk of progression compared to those without PSA response. Moreover, longer enzalutamide treatment (≥9 months) was noted to decrease the risk of death. PSA response, radiological response and duration of enzalutamide treatment may predict the improvement of survival in patients with mCRPC treated with enzalutamide. Key Words: Enzalutamide, Docetaxel, Castration-resistant prostate cancer, Overall survival, Progression-free survival.


  • Open Access

    How does COVID-19 fear and anxiety affect chemotherapy adherence in patients with cancer

    by Cengiz Karacin, Irem Bilgetekin, Fatma B Basal, Omur B Oksuzoglu

    Aim: To investigate how COVID-19 fear and anxiety (COV-FA) affects chemotherapy adherence in patients with cancer. Materials & methods: The records of 3661 patients with chemotherapy (CT) appointme...


  • Open Access

    Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies

    by Ece Esin, İrem Bilgetekin, Fatma Buğdaycı Başal, Ayşe Ocak Duran, Umut Demirci, Berna Öksüzoğlu

    Aim: In this retrospective study, the efficacy of adjuvant chemotherapy and its contribution to prognosis were investigated in patients diagnosed with different subgroups of ovarian carcinoma at stages 1–3. Material and Method Epithelial ovarian carcinoma cases treated at Ankara Oncology Training and Research Hospital of Health Sciences University between January 2014 and May 2018 were retrospectively analyzed. Results: A total of 145 patients were diagnosed and treated for EOC during the study period. According to histopathological subgroups, serous EOC was the most common (84.8%), followed by endometrioid (6.6%), mucinous (4.8%) and clear cell types (3.8%). Local recurrence and distant recurrences were observed in 39 (43.8%) and 7 (7.9%) cases in the serous EOC group, respectively. The median follow-up was 39 months (10–217 months). Median survival was 91.4 months (58.9–123.9 months) in the whole group and 100.9 months in serous EOC. Median survival in mucinous EOC was 26.2 months, whereas median survival in endometrioid EOC and clear cell EOC were not reached. A statistically significant difference of survival was found between serous and mucinous types of tumors (p: 0.04. Conclusions: According to the results of this study examining the survival outcomes of epithelial ovarian cancer subtypes after chemotherapy, there was a statistically significant difference between the prognosis of different epithelial ovarian cancer cases after taxane and platinum-containing adjuvant chemotherapy. Mucinous type of tumors exhibited less overall survival compared to endometrioid and clear cell types which needs to be confirmed with prospective clinical trials.